Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery ...Middle East

TAIPEI, Nov. 4, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract surgery patients by licensee, Grand Pharma (0512.HK). APP13007, a...

Hence then, the article about formosa pharmaceuticals announces successful top line results from cpn 303 a phase 3 trial in chinese subjects for the treatment of inflammation and pain after cataract surgery was published today ( Monday 04/11/2024 - 01:17 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery )

Also on site :

• OPEC+ makes first output decision after UAE exit – Reuters
• Strait of Hormuz blockade and other major naval sieges in modern times
• Trump doubts Iran deal, keeps threat of strikes